Our findings are highly relevant to AD pathogenesis, and direct inhibition of CCL2 signaling will reduce microglial activation in a fashion that will both lower Aβ deposition and improve behavioral outcomes. The gene discussed is CCL2; the disease is Alzheimer disease.